Prevalence of CD8 cytotoxic lymphocytes in human neoplasms.

Purpose: Immune checkpoint inhibitors have recently been approved by the US FDA as first and/or second line therapy in a subset of cancer types. Recent evidence suggests that the quantity of tumor infiltrating lymphocytes (TILs) influences the likelihood of response to immune checkpoint inhibitors. Here, we set out to assess the density of CD8 lymphocytes in a wide range of different cancer types and subtypes.